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Abstract
Recent evidence suggests that cannabinoid receptor agonists may regulate serotonin 2A (5-HT2A)
receptor neurotransmission in the brain, although no molecular mechanism has been identified.
Here, we present experimental evidence that sustained treatment with a non-selective cannabinoid
agonist (CP 55,940) or selective CB2 receptor agonists (JWH 133 or GP 1a) upregulate 5-HT2A
receptors in a neuronal cell line. Furthermore, this cannabinoid receptor agonist-induced
upregulation of 5-HT2A receptors was prevented in cells stably transfected with either CB2 or β-
Arrestin 2 shRNA lentiviral particles. Additionally, inhibition of clathrin-mediated endocytosis
also prevented the cannabinoid receptor-induced upregulation of 5-HT2A receptors. Our results
indicate that cannabinoid agonists might upregulate 5-HT2A receptors by a mechanism that
requires CB2 receptors and β-Arrestin 2 in cells that express both CB2 and 5-HT2A receptors. 5-
HT2A receptors have been associated with several physiological functions and neuropsychiatric
disorders such as stress response, anxiety & depression and schizophrenia. Therefore, these results
might provide a molecular mechanism by which activation of cannabinoid receptors might be
relevant to some cognitive and mood disorders in humans.
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Introduction
Marijuana (Cannabis sativa L.) is the most commonly abused illicit drug in the United States
(National Institute on Drug Abuse (NIDA) ,2009). According to recent epidemiological
data, marijuana and synthetic cannabinoids are the most prevalent illicit drugs used by 12th
graders in the United States (Cesar Fax ,2012). Indeed, more than one-third (36.4%) of high
school seniors reported using marijuana in 2011, including 11.4% who reported using
synthetic cannabinoids (Cesar Fax ,2012).
Cannabinoid agonists produce their effects by acting upon two cannabinoid receptors in the
brain, CB1 and CB2 receptors (Shoemaker et al. 2005;Atwood and Mackie ,2010;Bouaboula
et al. 1996). These receptors bind endocannabinoids and exogenous cannabinoids (such as
Δ9-THC) with high affinity (Bouaboula et al. 1996;Felder et al. 2006). CB1 and CB2
receptors, which couple to Gαi/o class of G-proteins, have presynaptic or postsynaptic
distribution in the brain (Onaivi et al. 2006;Felder et al. 2006;Kawamura et al. 2006;Brusco
et al. 2008). Furthermore, these receptors can activate ERK1/2 signaling possibly through a
β-Arrestin 2 (β-Arr2) dependent pathway (Atwood and Mackie ,2010;Bouaboula et al.
1996).
Behavioral reports have suggested that cannabinoid receptor agonists can regulate the
activity of serotonin 2A (5-HT2A) receptors (Darmani ,2001;Hill et al. 2006). However, the
molecular mechanism by which cannabinoid regulates 5-HT2A receptor signaling in the
brain is unknown. 5-HT2A receptors, which regulate the dopamine mesoaccumbens
pathway, play an important role in the regulation of stress, mood and impulse control and
the behavioral effects of several drugs of abuse (Bubar and Cunningham ,2006;Carrasco and
Van de Kar ,2003). Furthermore, impaired function of cortical 5-HT2A receptors has been
identified in several neurological and psychiatric disorders such as schizophrenia,
Alzheimer's disease, depression, anxiety, and eating disorders (Roth ,2011).
Here, we studied some mechanisms involved in the cannabinoid-induced upregulation of 5-
HT2A receptors in a neuronal cell line. Our results support the cannabinoid-induced




CLU213 cells, a rat neuronal cell line, were purchased from Cedarlane Laboratories
(Burlington, NC). Cells were grown on 100-mm2 plates treated with polystyrene (Corning
Incorporated, Corning, NY) and maintained in 5% CO2 at 37°C, in Dulbecco’s modified
eagle medium (Mediatech Inc, Manassas,VA) containing 10% fetal bovine serum (Thermo
Scientific, Logan, UT).
Quantitative Real-Time PCR
These reactions were prepared using QuantiFast SYBR Green PCR Kit (Qiagen, Valencia,
CA) and the ABI 7500 fast real time PCR system (Applied Biosystems, Foster City, CA) as
previously described (Singh et al. 2010). The primers used in this manuscript were: 5-HT2A
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GGCATGGACTGTGGTCATGA-3’). These primers have been validated in the literature
(Mato et al. 2009;Singh et al. 2010;Yang et al. 2011).
In all real-time PCR experiments, measurements were made from the number of cycles
required to reach the threshold fluorescence intensity [cycle threshold (Ct)]. Ct values for
each reaction were subtracted from Ct values for GADPH and then subtracted from Ct
values for vehicle-treated controls that served as a baseline, and the result was referred to as
ΔΔCt. Fold changes in gene expression were calculated as 2-ΔΔCt to reflect the fact that,
under optimal conditions, the amount of PCR product doubles with each amplification cycle.
Results were normalized to those obtained for amplifications of the same cDNA samples
using primers designed against GADPH, which acts as an internal standard, and averaged
for each treatment group.
To study the effect of non-selective and selective cannabinoid receptor agonists on 5-HT2A
mRNA, CLU213 cells were incubated with either vehicle (ethanol 0.01% final
concentration), CP 55,940 1 nM (non-selective CB1/CB2 agonist, Ki: 0.58 nM and 0.68 nM
for CB1 and CB2 receptors, respectively) (Showalter et al. 1996;Atwood et al. 2012);
ACEA 15 nM (selective CB1 agonist, Ki:1.4 nM and 3.1 µM for CB1 and CB2 receptors,
respectively) (Hillard et al. 1999;Rutkowska and Jachimczuk ,2004); GP 1a 1 nM (highly
selective CB2 agonist, Ki: 0.037 nM and 353 nM for CB2 and CB1 receptors, respectively)
(Gorantla et al. 2010), or JWH 133 30 nM (selective CB2 agonist, Ki: 3.4 nM and 677 nM
for CB2 and CB1 receptors, respectively ) (Huffman et al. 1999;Griffin et al. 1997) for 24
hours. In the Concanavalin A (ConA) experiment, cells were pretreated with 250 µg/ml
ConA for 20 minutes (Trincavelli et al. 2000) and then treated with different cannabinoid
agonists.
In a separate experiment utilized to examine the effect of an aminoakylindole on 5-HT2A
receptor mRNA levels, cells were treated with either vehicle (ethanol 0.01% final
concentration), GP 1a 1 nM, CP 559,940 1 nM, or JWH 073 40 nM (mildly selective CB1
receptor agonist, Ki: 8.9 nM and 38 nM for CB1 and CB2 receptors, respectively) (Aung et
al. 2000;Huffman et al. 2005) for 24 hours. In the Concanavalin A (ConA) experiment, cells
were pretreated with 250 µg/ml ConA for 20 minutes (Trincavelli et al. 2000) and then
treated with different cannabinoid agonists.
Western Blot
Membrane-associated and cytosolic-associated fractions were isolated using the
ProteoExtract™ Native Membrane Protein Extraction kit (Calbiochem, La Jolla, CA).
Nuclear-associated fractions were isolated using NE-PER ® Nuclear and Cytoplasmic
Extraction Reagents (Thermo Scientific, IL). Expression of membrane-associated 5-HT2A
receptors, CB2 receptors, β-Arr2, and nuclear-associated pERK was determined by Western
blot as previously described (Carrasco et al. 2006). The anti-5-HT2A receptor antibody was a
generous gift from Dr. Nancy A. Muma and the specificity of this antibody has been
validated in the literature (Singh et al. 2007). CB2 receptor, β-Arr2, and pERK antibody
were purchased from Santa Cruz, CA. Protein loading for each lane was verified using an
anti-actin antibody (Santa Cruz Biotechnology, Inc.). Negative controls included either the
omission of primary antibody or addition of preimmune rabbit immunoglobulins. Films
were analyzed densitometrically as described (Carrasco et al. 2006). All samples were
standardized to controls and normalized to their respective actin levels.
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To study the effect of GP1a, CP 55940, or ACEA on membrane-associated 5-HT2A receptor
levels, CLU213 cells were treated with either vehicle (ethanol 0.01% final concentration),
GP1a (1nM), CP 55,940 (1 nM) or ACEA (15 nM) for 72 hours. Cells were washed with
PBS every 24 hours and fresh vehicle, GP1a, CP55,940 or ACEA was added. To study the
effect of ConA on cytosolic-associated CB2 or nuclear-associated pERK levels, cells were
pretreated with ConA (250 µg/ml) and then 20 minutes later treated with either vehicle,
GP1a (1nM), or CP55,940 (1nM) for 15 minutes.
Lentivirus and stable transduction of shRNAs in CLU213 cells
β-Arrestin 2 shRNA (r), CB2 shRNA (r), copGFP control, control shRNA lentiviral
particles, polybrene, and puromyocin were purchased from Santa Cruz, CA. Optimal
transduction conditions were elucidated utilizing copGFP control lentiviral particles prior to
transduction with β-Arrestin 2 shRNA or CB2 shRNA lentiviral particles. Once optimal
transduction conditions had been defined, CLU213 cells in 24-well plates (2 X 104 cells/
well) were infected with either control, β-Arrestin 2, or CB2 shRNA lentivirial particles at a
multiplicity of infection (MOI) of 2 in complete medium containing a final concentration of
2 µg/ml of Polybrene. 48 hours post-infection, medium was changed to a virus-free complete
medium (no polybrene). Puromyocin (2 µg/ml final concentration) selection was initiated 24
hours later. Cells were analyzed for β-Arrestin 2 or CB2 knockdown one week after
initiation of puromyocin selection.
Statistics
All data are expressed as the mean ± S.E.M. Each experiment was run in triplicate. Data was
analyzed by an unpaired Student’s t-test or ANOVA (Newman-Keuls post-hoc test).
Results
Cells treated with either CP55,940 (CB1/CB2 agonist), GP1a (CB2 agonist) or JWH133
(CB2 agonist) showed significant (p<0.01) increases in 5-HT2A mRNA levels compared to
vehicle-treated controls (Fig.1A). However, no significant changes were detected in cells
treated with ACEA, selective CB1 agonist. Next we determined the effect of CP 55,940 (1
nM), ACEA (15 nM) and GP 1a (1 nM) on membrane-associated 5-HT2A receptor protein
levels. GP1a exhibits higher selectivity for CB2 receptors than JWH133 therefore we
utilized GP 1a to assess whether a highly selective CB2 receptor agonist would increase 5-
HT2A receptor protein levels (approx. 9,000- and 200-fold selectivity between CB2/CB1
receptors, respectively) (Gorantla et al. 2010;Griffin et al. 1997). We found that CP 55,940
treatment and GP1a treatment significantly (p<0.01) increased membrane-associated 5-
HT2A receptor protein levels (61±10% and 72 ± 10% increase, respectively)(Fig.1B and Fig.
1D). Treatment with ACEA did not significantly (p>0.05) modify the membrane-associated
5-HT2A receptor protein levels compared to controls (Fig. 1C).
We used cells stably transfected with CB2 or control shRNA lentiviral particles to study
whether the effect of cannabinoid agonists is mediated by CB2 receptors. CB2 shRNA
lentiviral particle treatment significantly (p<0.01) reduced both CB2 mRNA (Fig. 2A) and
protein levels (Fig. 2B) by approximately 80% compared to control-treated cells. CP55,940,
JWH133, and GP1a upregulated 5-HT2A mRNA in control shRNA cells (85 ± 5%, 84 ± 5%
and 84 ± 5% increase in 5-HT2A mRNA, respectively). Noteworthy, cells stably transfected
with CB2 shRNA showed no CP55,940, GP1a, or JWH133-induced increases in 5-HT2A
mRNA levels (Fig. 2C). The two-way ANOVA showed main effects of transfection (F1,173
=2.20,p<0.0001), CB2 agonists (F3,15.5 =0.1974,p<0.0001), and a main interaction between
these two factors (F3,27.66 =0.35,p<0.0001) on 5-HT2A mRNA levels.
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We also used cells stably transfected with either β-Arr2 or control shRNA lentiviral particles
to study the contribution of β-Arr2 on the cannabinoid-induced upregulation of 5-HT2A
receptors. Treatment with β-Arr2 shRNA lentiviral particles significantly (p<0.01) reduced
both β-Arr2 mRNA (Fig. 3A) and protein levels (Fig. 3B) by approximately 85%.
CP55,940, JWH133, and GP1a upregulated 5-HT2A mRNA in control shRNA treated cells
by 94 ± 10%, 84 ± 10% or 95 ± 7%, respectively. The cannabinoid agonist-induced
upregulation of 5-HT2A mRNA levels was significantly (p<0.05) reduced in cells stably
transfected with β-Arr2 shRNA lentiviral particles. CP55,940-, JWH133-, or GP1a-mediated
increases in 5-HT2A mRNA levels was 19 ± 9%, 0 ± 2% or 40 ± 10%, respectively (Fig.
3C). There was no significant difference (p>0.05) in the response mediated by either
CP55,940 and JWH133. However, treatment with GP 1a significantly (p<0.05) increased 5-
HT2A receptor mRNA levels in CB2 shRNA lentivirus treated cells compared to vehicle
treated controls. The two-way ANOVA showed main effects of transfection (F1,40.47
=1.66,p<0.0001), CB2 agonists (F3,13.92 =0.574,p<0.0001), and a main interaction between
these two factors (F3,4.12 =0.17,p<0.025) on 5-HT2A mRNA levels.
We then investigated whether CB2 receptor internalization is involved in the cannabinoid
agonist-induced upregulation of 5-HT2A receptors. Different methods are commonly used to
prevent clathrin-mediated internalization of receptors such as ConA treatment, use of
hypertonic sucrose, or depletion of intercellular potassium (Trincavelli et al. 2000;Macey et
al. 2010). We pretreated cells with vehicle or ConA prior to treatment with either vehicle,
CP55,940 or GP1a. As expected, CP55,940 and GP1a significantly upregulated 5-HT2A
mRNA levels compared to vehicle treated cells (approximately 90% increase, Fig.4A).
ConA pretreatment significantly (p<0.01) blocked the effect of CP55,940 (−9 ± 2%
reduction) and GP1a (−5 ± 2% reduction) on 5-HT2A mRNA levels compared to controls
(Fig.4A). The two-way ANOVA showed a main effect of ConA (F1,146.47 =2.22, p<0.0001),
CB2 agonists (F2,28.95 =0.437,p<0.0001), and a main between these two factors (F2,26.10
=0.394, p<0.0001) on 5-HT2A mRNA levels.
We then evaluated whether ConA pretreatment can modify the agonist-induced cytosolic
localization of CB2 receptors in a neuronal cell line. We isolated cytosolic fractions from
cells pretreated with vehicle or ConA and then treated with either vehicle, CP55,940 or
GP1a. Control cells treated with either CP55,940 or GP 1a showed significant increases in
the cytosolic levels of CB2 receptors (112 ± 30% and 90 ± 9%, respectively) compared to
controls (Fig.4B). ConA pretreatment significantly (p<0.01) reduced the vehicle, CP55,940-
and GP1a-induced increases in CB2 cytosolic levels. Furthermore, CP 55,940 treatment in
the ConA pretreated cells significantly increased CB2 receptor cytosolic levels compared to
ConA/Vehicle or ConA/GP 1a treated cells. The cytosolic CB2 levels were: 32 ± 7%, 7.5 ±
2%, 85 ± 13% for vehicle, GP1a and CP55,940 treated cells, respectively. The two-way
ANOVA showed a main effect of ConA pretreatment (F1,129 =83831,p<0.0001), CB2
agonist treatment (F2,19.28 =12.465,p<0.0001), and a main interaction between these two
factors (F2,8.909 =5760,p<0.025) on CB2 cytosolic levels.
Recent evidence shows that some cannabinoid ligands are more efficacious CB2 receptor
internalizers than others (Atwood et al. 2012). While CP55,940 is a classified as a good CB2
receptor internalizer, JWH-073 would classify as a poor CB2 receptor internalizer (Atwood
et al. 2012). There is no data regarding the properties of GP1a (Atwood et al. 2012). We
then tested the effect of either vehicle, JWH-073, GP1a or CP55,940 on 5-HT2A mRNA
levels in cells (Fig. 4C). We found that both GP1a and CP55,940 treatment produced
significant (p<0.01) increases in the 5-HT2A mRNA levels (110 ± 8% and 90 ± 7%,
respectively) but JWH-073 did not have any effect.
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CB2 internalization might also play a role in ERK1/2 activation (Lefkowitz and Shenoy ,
2005). Indeed, CB2 receptors might upregulate 5-HT2A receptors via activation of ERK1/2
(Chang et al. 2003). We studied the effect of ConA pretreatment on ERK1/2 activation by
measuring nuclear levels of pERK protein in cells treated with either vehicle or GP1a.
Significant (p<0.05) increases in the nuclear levels of pERK (35 ± 3% compared to controls)
were found in GP1a treated cells (Fig. 4D). ConA pretreatment significantly reduced the
basal and GP1a-induced increases in nuclear-associated pERK levels (Fig. 4D). The two-
way ANOVA showed a main effect of ConA pretreatment (F1,829 =55647,p<0.0001), GP1a
treatment (F2,30.60 =2052,p<0.0001) and a main interaction between these two factors
(F1,6.53 =438,p<0.021) on nuclear pERK levels.
Discussion
CB2 receptors are located not only in the periphery but also in several brain areas including
prefrontal cortex, hippocampus, amygdala, etc (Onaivi et al. 2008;den Boon et al.
2012;Gong et al. 2006;Garcia-Gutierrez et al. 2010). Furthermore, recent studies reported
that CB2 receptors are mainly localized post-synaptically (Onaivi et al. 2006;Brusco et al.
2008). These recent findings have led to a re-evaluation of the roles of CB2 receptors in the
brain. Interestingly, here we found that a potent non-selective cannabinoid agonist
(CP55,940) and selective CB2 receptor agonists (JWH133 and GP1a) induced a strong
upregulation of 5-HT2A receptors in neuronal cells. This cannabinoid–induced upregulation
was not mimicked by a CB1 agonist (ACEA) and was absent in cells stably transfected with
CB2 shRNA (Fig.2) indicating that CB2 receptors are required for this cannabinoid-
mediated upregulation of 5-HT2A receptors.
Accumulating evidence shows that different CB2 receptor agonists can distinctly regulate
multiple effector pathways, a phenomenon known as functional selectivity (Atwood et al.
2012;Lefkowitz and Shenoy ,2005;Shoemaker et al. 2005). This transmission of
extracellular signals to the interior of the cell is a function of plasma membrane receptors
that can direct the recruitment, activation, and scaffolding of cytoplasmic signaling
complexes via β-arrestins (Lefkowitz and Shenoy ,2005). Specifically, a β-Arr2 dependent
pathway could mediate the CB2-induced activation of ERK1/2 signaling and the
internalization of CB2 receptors (McGuinness et al. 2009;Atwood et al. 2012). Our results
support a key role of β-Arr2 in the cannabinoid-induced upregulation of 5-HT2A receptors
as cells stably transfected with β-Arr2 shRNA lentivirus (Fig. 3) failed to upregulate 5-HT2A
receptors in response to either CP55,940 or JWH133. GP 1a-mediated upregulation of 5-
HT2A mRNA levels was significantly reduced in β-Arr2 shRNA lentivirus treated cells
compared to control shRNA treated cells. Although, we do not know the mechanism
mediating this effect we speculate that the remaining β-Arr2 protein levels (approx.15–20%)
could be enough to produce significant increases in 5-HT2A mRNA levels. Alternatively, GP
1a could be triggering this upregulation (at least in part) through a different signaling
mechanism than the one triggered by CP55,940 or JWH 133.
β-Arr2 could mediate the upregulation of 5-HT2A receptors by regulating internalization of
CB2 receptors (Atwood et al. 2012). ConA pretreatment of cultured cells is used to prevent
clathrin-mediated internalization of receptors (Trincavelli et al. 2000;Macey et al. 2010).
Interestingly, ConA pretreatment prevented the CP55,940- and GP1a-induced increases in 5-
HT2A receptor mRNA levels in cultured cells (Fig.4A). Our results also showed that ConA
pretreatment also prevented the CP55,940 or GP1a increases in CB2 receptor cytosolic
levels (Fig.4B). Noteworthy, ConA pretreatment even reduced the basal cytosolic CB2
protein levels (Fig.4B). This suggests that ConA might prevent the basal trafficking of CB2
receptors between the membrane and cytosol in neuronal cells. Similarly, Atwood et al
(2012) described significant increases in membrane-associated levels of CB2 receptors in
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sucrose treated cells (Atwood et al. 2012) further indicating that protocols utilized to prevent
clathrin-mediated endocytosis alter basal trafficking of the CB2 receptors between the
membrane and the cytosol.
The previous experiments suggest that the degree of internalization of CB2 receptors could
play an important role in the upregulation of 5-HT2A receptors. Atwood et al. (2012)
identified different classes of CB2 agonists that differ substantially in their ability to
promote CB2 receptor internalization (Atwood et al. 2012). Cannabinoid agonists such as
CP55,940 and JWH133 were the most efficacious CB2 receptor internalizers, while
aminoalkylindoles which include cannabinoid ligands, such as JWH-073 and WIN55,212-2,
were the least effective or failed to promote CB2 receptor internalization (Atwood et al.
2012). We found that CP55,940, but not JWH-073, induced 5-HT2A upregulation (Fig. 4C),
suggesting that upregulation of 5-HT2A receptors is dependent on the ability of the agonists
to promote internalization of CB2 receptors. This is consistent with the experiments
previously discussed where ConA pretreatment prevented the cannabinoid-mediated
increases in 5-HT2A mRNA levels (Fig. 4A).
CB2 receptor-mediated upregulation of 5-HT2A receptors might involve transcription factors
that are located downstream of ERK and that target the promoter region of the 5-HT2A
receptor gene such as CREB and AP-1 (Chang et al. 2003). Here, we found that a selective
CB2 receptor agonist (GP1a) induced ERK1/2 activation (Fig. 4D), suggesting that the CB2
receptor mediated-upregulation of 5-HT2A receptors involve activation of the ERK1/2
signaling pathway.
In summary, our results indicate that cannabinoid agonists would upregulate 5-HT2A
receptors by a mechanism that requires CB2 receptors and β-Arr2 activation in cells that
express both CB2 and 5-HT2A receptors. This upregulation could be mediated by a
mechanism that involves internalization of CB2 receptors and ERK1/2 activation. Indeed,
compounds that do not internalize CB2 receptors such as JWH-073 do not induce 5-HT2A
upregulation. It is then possible that cannabinoid agonists that upregulate 5-HT2A receptors
mediate their effect by recruiting β-Arr2 to the membrane, enhancing ERK1/2 activation,
and also promoting CB2 receptor internalization. 5-HT2A receptors have been associated
with several physiological functions and neuropsychiatric disorders such as stress response,
anxiety & depression and schizophrenia (Roth ,2011;Carrasco and Van de Kar ,2003).
Cannabinoid-induced upregulation of 5-HT2A receptors may precipitate the onset of mental
disorders associated with dysfunction of 5-HT2A receptor neurotransmission as it has been
recently suggested (Large et al. 2011).
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Figure 1. Cannabinoid-induced upregulation of 5-HT2A receptors
(A) Increased 5-HT2A receptor mRNA levels in cells treated with either CP55,940, JWH
133, or GP1a. (**p<0.01 significant effect of CP55,940,JWH133, and GP1a treatment
compared to vehicle-treated controls). (B) Increased membrane-associated 5-HT2A receptor
protein levels in cells treated with CP 55,940. (**p<0.01 significant effect of CP 55,940
treatment compared to vehicle-treated controls). (C) ACEA treatment does not alter
membrane-associated 5-HT2A receptor protein levels (p>0.05). (D) Increased membrane-
associated 5-HT2A receptor protein levels in cells treated with GP 1a. (**p<0.01 significant
effect of GP 1a treatment compared to vehicle-treated controls). The data represent mean ±
SEM (n=3).
Franklin et al. Page 11













Figure 2. CB2 receptors are necessary for CP55,940, JWH133, and GP1a-induced upregulation
of 5-HT2A receptors
(A) Reduced CB2 mRNA levels in cells treated with CB2 shRNA lentiviral particles.
(**p<0.01 significant effect of CB2 shRNA compared to control shRNA treated cells). (B)
Reduced CB2 protein levels in cells treated with CB2 shRNA lentiviral particles compared
to control shRNA lentiviral particle treated controls. (C) CB2 shRNA lentivirus transfection
prevents CP55,940, JWH133 and GP1a-induced increases in 5-HT2A receptor mRNA.
**p<0.01, significant effect of CP55,940, JWH133, and GP1a treatment on 5-HT2A receptor
mRNA levels in control shRNA lentivirus transfected cells compared to vehicle-treated
controls. ##p<0.01, significant effect of CB2 shRNA lentivirus transfection on the
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CP55,940, JWH133, and GP1a-induced upregulation of 5-HT2A receptors. The data
represent mean ± SEM (n=3).
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Figure 3. β-Arr2 is necessary for CP55,940, JWH133, and GP1a-induced upregulation of 5-
HT2A receptors
(A) Reduced β-Arr2 mRNA levels in cells treated with β-Arr2 shRNA lentiviral particles.
(**p<0.01 significant effect of β-Arr2 shRNA compared to control shRNA treated cells).
(B) Reduced β-Arr2 protein levels in cells treated with β-Arr2 shRNA lentiviral particles
compared to control shRNA lentiviral particle treated controls. (C) β-Arr2 shRNA lentivirus
transfection prevents CP55,940, JWH133 and GP1a-induced increases in 5-HT2A receptor
mRNA. **p<0.01, significant effect of CP55,940, JWH133, and treatment on 5-HT2A
receptor mRNA levels in control shRNA transfected cells compared to vehicle-treated
controls. ##p<0.01 or #p<0.05, significant effect of β-Arr2 shRNA transfection on the
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CP55,940 and JWH133 or GP1a-induced upregulation of 5-HT2A receptors. @p<0.05,
significant effect of GP 1a treatment in β-Arr2 shRNA transfected cells compared to
vehicle-treated β-Arr2 shRNA transfected cells. The data represent mean ± SEM (n=3).
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Figure 4. CP55,940 and GP1a may upregulate 5-HT2A receptors via CB2 receptor
internalization
(A) ConA pretreatment prevents CP55,940 and GP1a-induced increases in 5-HT2A receptor
mRNA. **p<0.01, significant effect of CP55,940 and GP1a treatment on 5-HT2A receptor
mRNA levels compared to vehicle-treated controls. ##p<0.01, significant effect of ConA
pretreatment on the CP55,940 and GP1a-induced upregulation of 5-HT2A receptors. (B)
ConA pretreatment prevents CP55,940 and GP1a-induced increases in cytosolic-associated
CB2 receptor protein levels. **p<0.01, significant effect of CP55,940 and GP1a treatment
on cytosolic CB2 receptor protein levels compared to vehicle-treated controls. ##p<0.01,
significant effect of ConA pretreatment on the CP55,940 and GP1a-induced increases in
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cytosolic CB2 receptor protein levels. @p<0.05, significant effect CP 55,940 treatment in
ConA pretreated cells compared to ConA/vehicle or ConA/GP1a treated cells. (C) JWH-073
does not significantly (p>0.05) alter 5-HT2A receptor mRNA levels. **p<0.01, significant
effect of CP55,940 and GP1a treatment on 5-HT2A receptor mRNA levels compared to
vehicle-treated controls. (D) ConA pretreatment prevents GP1a-induced increases in nuclear
pERK. **p<0.01, significant effect of GP1a treatment on nuclear pERK levels compared to
vehicle-treated controls. ##p<0.01, significant effect of ConA pretreatment on GP1a-
induced increases in nuclear pERK levels. The data represent mean ± SEM (n=3).
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